215 related articles for article (PubMed ID: 15160318)
21. Octreotide acetate is efficacious and safe in children for treating diarrhea due to chemotherapy but not acute graft versus host disease.
Pai V; Porter K; Ranalli M
Pediatr Blood Cancer; 2011 Jan; 56(1):45-9. PubMed ID: 21108438
[TBL] [Abstract][Full Text] [Related]
22. A pilot study of Octreotide LAR vs. octreotide tid for pain and quality of life in chronic pancreatitis.
Lieb JG; Shuster JJ; Theriaque D; Curington C; Cintrón M; Toskes PP
JOP; 2009 Sep; 10(5):518-22. PubMed ID: 19734628
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of the long-acting repeatable formulation of the somatostatin analogue octreotide in postoperative dumping.
Arts J; Caenepeel P; Bisschops R; Dewulf D; Holvoet L; Piessevaux H; Bourgeois S; Sifrim D; Janssens J; Tack J
Clin Gastroenterol Hepatol; 2009 Apr; 7(4):432-7. PubMed ID: 19264574
[TBL] [Abstract][Full Text] [Related]
24. Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies.
Ippoliti C; Champlin R; Bugazia N; Przepiorka D; Neumann J; Giralt S; Khouri I; Gajewski J
J Clin Oncol; 1997 Nov; 15(11):3350-4. PubMed ID: 9363865
[TBL] [Abstract][Full Text] [Related]
25. Control of irinotecan-induced diarrhea by octreotide after loperamide failure.
Barbounis V; Koumakis G; Vassilomanolakis M; Demiri M; Efremidis AP
Support Care Cancer; 2001 Jun; 9(4):258-60. PubMed ID: 11430421
[TBL] [Abstract][Full Text] [Related]
26. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.
Kvols LK; Oberg KE; O'Dorisio TM; Mohideen P; de Herder WW; Arnold R; Hu K; Zhang Y; Hughes G; Anthony L; Wiedenmann B
Endocr Relat Cancer; 2012 Oct; 19(5):657-66. PubMed ID: 22807497
[TBL] [Abstract][Full Text] [Related]
27. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
[TBL] [Abstract][Full Text] [Related]
28. Octreotide for the treatment of diarrhoea in patients with ileal pouch anal anastomosis: a placebo-controlled crossover study.
Van Assche G; Ferrante M; Vermeire S; Noman M; Rans K; Van der Biest L; Penninckx F; Wolthuis A; Rutgeerts P; D'Hoore A
Colorectal Dis; 2012 Apr; 14(4):e181-6. PubMed ID: 21951549
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of depot long-acting release octreotide therapy in severe dumping syndrome.
Penning C; Vecht J; Masclee AA
Aliment Pharmacol Ther; 2005 Nov; 22(10):963-9. PubMed ID: 16268971
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the efficacy of octreotide LAR in the treatment of Crohn's disease associated refractory diarrhea.
Martelli L; Colard A; Fontaine F; Deflandre J; Bastens B; Louis E
Scand J Gastroenterol; 2017 May; 52(5):564-569. PubMed ID: 28270045
[TBL] [Abstract][Full Text] [Related]
31. Octreotide in the management of diarrhea induced by graft versus host disease.
Ippoliti C; Neumann J
Oncol Nurs Forum; 1998 Jun; 25(5):873-8. PubMed ID: 9644703
[TBL] [Abstract][Full Text] [Related]
32. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial.
Cascinu S; Fedeli A; Fedeli SL; Catalano G
J Clin Oncol; 1993 Jan; 11(1):148-51. PubMed ID: 8418225
[TBL] [Abstract][Full Text] [Related]
33. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer.
Matulonis UA; Seiden MV; Roche M; Krasner C; Fuller AF; Atkinson T; Kornblith A; Penson R
J Pain Symptom Manage; 2005 Dec; 30(6):563-9. PubMed ID: 16376743
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and tolerability of long-acting octreotide in the treatment of thymic tumors: results of a pilot trial.
Longo F; De Filippis L; Zivi A; Vitolo D; Del Signore E; Gori B; Diso D; Anile M; Venuta F; De Giacomo T; Coloni CF
Am J Clin Oncol; 2012 Apr; 35(2):105-9. PubMed ID: 21325939
[TBL] [Abstract][Full Text] [Related]
35. Successful treatment of congenital hyperinsulinism with long-acting release octreotide.
Le Quan Sang KH; Arnoux JB; Mamoune A; Saint-Martin C; Bellanné-Chantelot C; Valayannopoulos V; Brassier A; Kayirangwa H; Barbier V; Broissand C; Fabreguettes JR; Charron B; Thalabard JC; de Lonlay P
Eur J Endocrinol; 2012 Feb; 166(2):333-9. PubMed ID: 22048969
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study.
Ronchi CL; Boschetti M; Degli Uberti EC; Mariotti S; Grottoli S; Loli P; Lombardi G; Tamburrano G; Arvigo M; Angeletti G; Boscani PF; Beck-Peccoz P; Arosio M;
Clin Endocrinol (Oxf); 2007 Oct; 67(4):512-9. PubMed ID: 17555511
[TBL] [Abstract][Full Text] [Related]
37. Long-acting octreotide as secondary prevention of chemotherapy-induced diarrhea: proof of concept.
VAN DEN Heuvel B; Peeters M; Hendlisz A; VAN DEN Eynde M; Machiels G; Dero I; Geboes K; DE Man M; Hendrickx K; Delaunoit T; Monsaert E; Vanderstraten E; VAN Laethem JL; Lybaert W; Holbrechts S; Rolfo C
Minerva Chir; 2016 Jan; ():. PubMed ID: 26771252
[TBL] [Abstract][Full Text] [Related]
38. Somatostatin analogs and prednisone in advanced refractory thymic tumors.
Palmieri G; Montella L; Martignetti A; Muto P; Di Vizio D; De Chiara A; Lastoria S
Cancer; 2002 Mar; 94(5):1414-20. PubMed ID: 11920496
[TBL] [Abstract][Full Text] [Related]
39. The efficacy of octreotide in the therapy of acute radiation-induced diarrhea: a randomized controlled study.
Yavuz MN; Yavuz AA; Aydin F; Can G; Kavgaci H
Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):195-202. PubMed ID: 12182992
[TBL] [Abstract][Full Text] [Related]
40. [Management of chemotherapy induced diarrhea].
Schultz M; Schölmerich J; Kullmann F
Z Gastroenterol; 2004 Jun; 42(6):527-38. PubMed ID: 15190449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
